TAI · 6446.TW
PharmaEssentia Corporation
NT$1,190.00-NT$50.00 (-4.03%)
PharmaEssentia Corporation’s quoted price sits in the upper half of its reported 52-week range, 27.66% below the high.
Loading market information…
TWO · 6634.TWO · TWD
Stock price
Quote as of Oct 30, 2026, 06:51 AM UTC. Cached market data; not a live quote.
One-year closing-price history · TWD. Historical prices are not a forecast.
Sinew Pharma Inc.’s quoted price sits in the lower half of its reported 52-week range, 36.47% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE COMPANY BEHIND THE TICKER
Sinew Pharma Inc. is a biopharmaceutical enterprise dedicated to the research, development, and commercialization of new therapeutics. Its core mission revolves around pioneering innovative solutions for hepatotoxicity-free acetaminophen and addressing various fatty liver conditions. The company's robust pipeline features SNP-610, a drug candidate currently advancing through Phase II clinical trials in Taiwan for the treatment of non-alcoholic steatohepatitis (NASH). Another early-stage compound, SNP-630, is also in preclinical development, targeting NASH. Beyond liver disease, Sinew Pharma is progressing SNP-810 for its analgesic and antipyretic properties. Furthermore, the firm is developing SNP-830 and SNP-840, positioned as liver-safe pain medications specifically for the United States market. Established in 2014, Sinew Pharma Inc. maintains its headquarters in Taipei City, Taiwan.
Latest available per-share figures in TWD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 08:46 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
NT$1,190.00-NT$50.00 (-4.03%)
PharmaEssentia Corporation’s quoted price sits in the upper half of its reported 52-week range, 27.66% below the high.
NT$159.00-NT$2.50 (-1.55%)
Lin BioScience, Inc.’s quoted price sits in the upper half of its reported 52-week range, 23.19% below the high.
NT$39.05-NT$1.75 (-4.29%)
Pell Bio-Med Technology Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 97.38% below the high.
NT$379.00-NT$13.00 (-3.32%)
Bora Pharmaceuticals Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 41.78% below the high.
NT$167.50-NT$5.00 (-2.9%)
Lotus Pharmaceutical Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 54.67% below the high.
NT$419.00-NT$3.50 (-0.83%)
Pegavision Corp.’s quoted price sits in the upper half of its reported 52-week range, 4.12% below the high.
NT$45.80-NT$1.20 (-2.55%)
Oneness Biotech Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 40.29% below the high.
NT$132.50-NT$5.00 (-3.64%)
Handa Pharmaceuticals, Inc.’s quoted price sits in the upper half of its reported 52-week range, 14.52% below the high.
